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Abstract
Introduction: The various distribution of fat mass (FM) and lean mass (LM) during COPD development is not yet researched. 
Material and methods: 82 male patients (40–67 years) with acute exacerbation of COPD and 19 comparable healthy males (the 
control group) were examined by dual-energy X-ray absorptiometry. The patients were divided into 3 groups according to COPD 
severity: 1st — 19 (GOLD I stage); 2nd — 43 (GOLD II) and 3rd — 20 (GOLD III).
Results: The patients of 3rd group had lower indices of FM, LM, bone mineral component (BMC) vs. the control and 1st, 2nd groups. 
A significant increase in FM share was noted in android and gynoid regions, trunk, legs and arms in 2nd groups vs. the control 
with the decline of these parameters in the 3rd group below the control level. A greater proportion of FM in 1st and 2nd groups was 
distributed in android and trunk regions vs. the control. TNF-a and leptin levels were significantly increased by 12%, 15% 17% 
and by 18%, 75%, 79% respectively in 1st, 2nd, 3rd groups vs. the control, while free testosterone level was lower in these groups 
vs. the control (by 28%, 30% and 47% respectively; p < 0,05). 
Conclusions: Body mass index (BMI) was within the control range in mild-moderate COPD patients in spite of LM, FM and BMC 
changes. The level of LM and BMC was decreased during COPD progression, while FM was increased in mild-moderate COPD 
and then it was decreased in severe COPD. 
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Introduction
The picture of systemic manifestations of 
COPD is not complete without the evaluation of 
patient’s body composition (BC) parameters [1]. 
Repeated COPD exacerbations are accompanied 
by an impaired energy balance that has a nega-
tive consequence on patient’s BC [2]. In turn, BC 
abnormalities may be a significant contributor to 
the low-grade systemic inflammation and may 
indirectly stimulate stimulate COPD progres-
sion. Thus, BMI loss (from 10% in mild to 50% 
in severe COPD) has an unfavorable impact on 
disease development due to decreased skeletal 
and respiratory muscle strength (with subsequent 
lower exercise capacity), resistance to infection 
as well as the higher frequencies of exacerbations 
[3–5]. The reasons for progressive loss of tissue 
mass and BMI include [6, 7]: increased load on the 
respiratory muscles (enhanced by 15% breathing 
work and its energy costs at rest and during exer-
cise), a high level of proinflammatory cytokines 
and basic metabolism (increased by 25% vs. the 
healthy persons), to a smaller degree — expressed 
hypoxia and tissue oxygen debt, oxidative stress, 
the use of long acting b2-agonists and teophylline, 
smoking,hypoandrogenism, impaired regulation 
of hormones that reduces food intake, disorders 
of gastro-intestinal tract and protein metabolism 
(with increased protein degeneration). 
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BMI does not give the complete information 
about BC changes in COPD patients. Thus, loss of 
LM is not always accompanied by a loss of BMI 
and may occur in the case of normal patient’s BMI 
level against the background of FM component 
excess [8]. Only 17% of the patients with chronic 
respiratory failure had a BMI < 20 kg/m2 as well as 
only 5% of mild COPD patients had a BMI < 18.5 
kg/m2 vs. 30% of patients with severe COPD [9, 
10]. Three malnutrition profiles can be identified 
in advanced COPD [11]: underweight patients 
with concomitant depletion of body LM (60%) 
or with a normal LM (20%) and the patients of 
normal body weight with depletion of LM. A shift 
in BC structure towards a relative abundance of 
FM and reduced LM during COPD exacerbation 
(due to increased: hypoxemia, sympathetic tone, 
using b2-agonists and systemic corticoids — sCS) 
was revealed. LM loss (significant problem in 
1/3 of moderate to severe COPD patients) may 
adversely affect the peripheral skeletal and respi-
ratory muscles (development of their weakness) 
and respiratory function [5, 12]. 
The metabolic syndrome is observed in up to 
53% of COPD patients in GOLD grade 2 [13] and it 
was associated with higher levels of the systemic 
inflammation markers and frequency of exacer-
bations [14]. Overweight and obesity were often 
observed (in 1/3 and 1/5 of cases respectively) 
in COPD patients [15] and they did not worsen 
the respiratory function and symptoms in many 
cases of mild-to-moderate COPD as well as they 
had even a protective effect in relation to mortal-
ity [10]. But severe obesity favors the disorders 
of carbohydrate metabolism, pulmonary dys-
function (reduced compliance of the chest wall, 
lung volume and impaired airway function) and 
appearance of cardiovascular pathology [14, 16]. 
Hormonal changes are also closely linked to 
disturbed BC. Gradually decreasing levels of cir-
culated androgens in males with age is related to 
increased levels of total and abdominal body FM 
[17]. A key role in the relationship between lung 
pathology and adipose tissue play adipokines 
(APN) — leptin and adiponektin, for which im-
portant source is an abdominal subcutaneous 
and visceral FM. APN significantly influence 
the inflammatory process, immune response, 
lipid metabolism and regulation of energy bal-
ance [18]. Pro-inflammatory effects of APN may 
dominate under the certain conditions. Thus, 
visceral obesity and visceral FM in overweight 
COPD patients may be associated with a high 
level of proinflammatory cytokines (TNF-a) and 
leptin as well as have a greater inflammatory ef-
fect [19, 20]. It was shown, that sCS and TNF-a 
induce increased leptin level in normal subjects, 
besides TNF-a may decrease all the components 
of BC. The increased levels of TNF-a and leptin 
in blood circulation favor decreased appetite and 
food intake in COPD patients, mostly with severe 
hypoxia, which induces increased leptin expres-
sion and intensified fat metabolism in COPD [12, 
19]. Leptin resistance is common in overweight 
COPD patients and results in lung hypoventilation 
[21]. Systemic leptin concentration may be dispro-
portionately higher in COPD, reflecting a greater 
airway inflammation and disease severity [22]. 
The purpose of this study was to evaluate dis-
tribution of BC as well as the relationship between 
the latter and TNF-a, leptin and free testosterone 
levels in relation to COPD development.
Material and methods
The study was undertaken at the Pulmonolo-
gy Department of the 10th Minsk Clinical Hospital 
in the years 2009–2013. All participants gave their 
written informed consent. The study protocol was 
approved by the Human Studies Committee on 
Research Ethics at the Belarusian State Medical 
University. The inclusion criteria for the study 
were the following: males aged 40–69 years with 
different COPD grades and FEV1 increase < 15% 
in bronchodilator test. Exclusion criteria includ-
ed substantial uncontrolled co-morbidities that 
may affect nutritional status (uncontrolled heart 
failure and diabetes, chronic renal failure, neo-
plasms). The study group consisted of 82 COPD 
male patients with acute exacerbation who were 
divided into three groups according to the severity 
of disease (mild — COPD1, moderate — COPD2 
and severe — COPD3) using post-bronchodilator 
FEV1 and clinical symptoms. The diagnosis of 
COPD and its severity was based on the GOLD 
guidelines published in 2011. The intensity of 
dyspnea was defined according to a modified MRC 
questionnaire. The clinical investigation of these 
patients on admission included: self-reported 
co-morbidities, smoking status and previous treat-
ment, spirometry (using a portable spirometer 
“Spirovit SP-10” of “Shiller”), physical examina-
tion, day-time pulseoximetry, chest radiography 
and blood laboratory analyses. The patients 
(mostly COPD2–3) were treated with a combination 
of inhaled long-acting anticholinergic (or b2-ago-
nists) plus inhaled and sometimes sCS (5 days of 
dexametasone intravenously, 4 mg a day) as well 
as broad spectrum antibiotics if there was clinical 
evidence of Type 1 or 2 exacerbation according 
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to Anthonisen criteria. The control group con-
sisted of 19 healthy male persons of comparable 
age, smoking status, BMI and without history of 
chronic diseases.
TNF-a, leptin and free testosterone levels 
were detected by immynoenzyme (ELISA) meth-
ods. Distribution of BC parameters was measured 
using dual-energy X-ray absorptiometry (DXA) 
(“Prodigy Lunar”, General Electric Medical Sys-
tems, USA). We calculated: FM index (FMI = 
FM/height2), LM index (LMI = LM/height2) that 
reflects non-fat and non-bone soft tissue content, 
skeletal muscle index (SMI = fat-free mass of 
arms + legs/height2) and bone mineral compo-
nent index (BMCI = bone mineral component of 
body/height2). 
The statistical analysis was performed us-
ing Statistica 8.0 software (2007, Statsoft Inc., 
USA). The preliminary analysis of the variables 
under consideration was a Shapiro-Wilk test 
of correspondence to normal distribution. The 
results of the analysis were shown as median 
and interquartile range (25–75%) because all the 
parameters differed from normal distribution. 
The comparison of non-parametric parameters in 
two independent groups was carried out using a 
Mann-Whitney test, while in three or more inde-
pendent groups it was performed using the Kru-
skal-Wallis rank sum test. Fisher’s exact test was 
used to detect statistically significant differences 
between independent groups according to the 
frequency characteristic of the investigated pa-
rameter. Spearman’s rank correlation coefficient 
(rs) was used to describe the relationship between 
the two quantitative variables that differed from 
normal distribution. The level of statistical sig-
nificance was set at p < 0.05.
Results
As shown in Table 1, the control group did 
not differ from COPD1 patients in terms of me-
dian age, the percent of patients under 60 years, 
BMI and intensity of smoking. COPD1 patients 
had only slightly decreased ventilation param-
eters compared with the controls. A progressive 
Table 1.  Baseline characteristics of the control group and COPD patients groups according to different degrees of airflow 
limitation severity (GOLD spirometry level, 2011) on admission (Me; 25, 75)
Parameters Control
n = 19
COPD1
n = 19
COPD2
n = 43
COPD3
n = 20
Median age (years):
< 60/> 60 years (%)
52 (47; 55)
70/30
55 (51; 58)
79/21
57 (53; 60)*
66/34
62 (56; 67)*, **, ***
50/50 
Body mass index [kg/m2] 28.6 
(27.5; 29.2)
29.0 
(27; 32.5)
30,3*
(26.4; 32.2)
22.9*, **, ***
(20.7; 27.7) 
Present smokers (%) 62 68 77 96*, **
Smoking history, index 
packs/years
18 
(10; 30) 
20 
(12; 30)
21 
(12; 30)
30*, ***
(25; 40)
Median duration of COPD 
(years)
– 3 
(1; 6) 
9 
(4; 12)
13**, ***
(10; 19)
FVC (% pred.) 100 (98; 112) 86 (75; 90)* 57 (48; 66)*, ** 39 (32; 46)*, **, ***
FEV1 (% pred) 86 (77; 92) 82 (78; 87)* 56 (50; 65)*, ** 33 (22; 44)*, **, ***
FEV1/FVC (%) 95 (89; 104) 70 (62; 72)* 67 (57; 75)*, ** 51 (39; 58)*, **, ***
SatO2 (%) 97 (96; 97) 97 (96; 97) 96 (95; 98) 93 (90; 95)*, **, ***
C-reactive protein [mg/dL] 0.3 
(0.1; 1.8) 
0.3 
(0.1; 1.3)
4.3*, **
(1.9; 8.3)
3.3*, **
(1.3; 5.3)
Home treatment:
corticoids inhaled/intermit-
tently oral (%);
with inhaled long acting 
anticholinergic (%);
with inhaled long acting 
b2-agonists
–
–
–
–
35/2
22
1
43/15***
7
17***
*p < 0.05 vs. the control group; **p < 0.05 vs. COPD1; ***p < 0.05 vs. COPD2 group; Me — median, 25–75% — interquartile range
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decrease in ventilation parameters was noted as 
the disease became worse: FVC dropped from 
86% in COPD1 to 39% in COPD3; FEV1 and blood 
oxygen saturation dropped from 82% to 33% 
and from 97% to 93% in COPD1 and COPD3 re-
spectively. A significant increase in the number 
of exacerbations for the past year was found in 
COPD3 compared with COPD1, 2. COPD3 patients 
had a significantly higher median age, disease 
duration, MRC breathlessness index and the 
number of current smokers than the control 
group and COPD1, 2 patients, whereas mean BMI 
of COPD3 group was significantly lower than in 
the latter. 
As seen from Figure 1, the part of BMI within 
the normal range was increased (from 10% in 
COPD1 to 58% in COPD3) in the course of COPD 
development, while overweight and obesity were 
naturally decreased as COPD became worse. 
Thus, overweight was detected in 50%, 28% and 
16% of COPD1, 2, 3 patients respectively.
We revealed that the number of patients with 
decreased LMI level was higher among the pa-
tients with normal BMI as the disease progressed 
(Table 2). We did not detect these patients in 
COPD1 group, whereas 1 and 6 such patients were 
revealed in COPD2, 3 groups respectively. 
Meanwhile decreasing LMI was detected 
in 5% of COPD3 patients with low BMI and in 
30% of these patients against the background of 
normal values of BMI. The latter was decreased 
only in severe COPD, but it was in the normal 
range (or increased to some extent) in most of 
the observed patients. LMI, BMCI and SMI did 
not differ in COPD1 from the control (Table 3), 
whereas in COPD3 these parameters (including 
FMI) were significantly decreased compared with 
the control and COPD1, 2.
More changes of FM were detected in the 
trunk and android regions and fewer — in legs 
and arms. The changes of FM distribution in 
different body regions had the phased charac-
ter. There was no difference of FM distribution 
between COPD1 group and the control. But we 
revealed significant increase of FM share in arms, 
legs, trunk, android and gynoid regions in COPD2 
group (by 30%, 31%, 24%, 18% and 19% respec-
tively vs. the control). Then, in COPD3 group these 
parameters were decreased to the control values. 
Deposition of FM in definite body regions 
(particularly in trunk and android zone) in COPD 
patients may be associated with the certain 
co-morbidities, such as arterial hypertension 
(AH). Therefore we additionally assessed the 
influence of BC distribution upon the presence 
of AH. Thus, we detected an increased number of 
COPD patients with concomitant AH: 41%, 81% 
and 74% in COPD1, 2, 3 groups respectively. 
Table 2. Distribution of COPD patients with different severity according to the degree of BMI and LMI (%)
BMI (kg/m2) COPD1 COPD2 COPD3
LMI (kg/m2) 
< 16.6 > 16.6 < 16.6 > 16.6 < 16.6 > 16.6
Deficiency
BMI < 18.5
0 0 0 0 5 0 
Normal
BMI ≥ 18.5–24.9
0 10 2 17 30*** 26 
Overweight
BMI 25.0–29.9
0 50 3 22** 0 17**
Obesity
BMI > 30.0
0 40 0 56 0 22**, *** 
The designations are the same as in the Table 1
Figure 1. Distribution of COPD patients according to their BMI
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Table 3. Distribution of FMI, LMI, BMCI and SMI levels (kg/м2) among males according to COPD severity (Me; 25%,75%)
Parameter Control
n = 19
COPD1
n = 19
COPD2
n = 43
COPD3
n = 20
FMI 7.2
(6.2; 7.7)
8.3*
(6.2; 10.1)
9.7*
(6.8; 11.0)
4.7*, **, ***
(3.1; 9.3)
LMI 20.3
(19.9; 22.0)
20.8
(20.1; 21.4)
20.1**
(18.8; 21.2)
17.7*, **, ***
(16.5; 18.9)
BMCI 1.06
(0.99; 1.12)
1.04
(0.97; 1.08)
1.01
(0.92; 1.08)
0.89*, **, ***
(0.83; 0.94)
SMI 9.34
(8.76; 9.70)
9.41
(8.81; 9.74)
8.92*, **
(8.05; 9.51)
7.61*, **, ***
(7.13; 8.38)
The designations are the same as in the previous Table 1
FMI — fat mass index, LMI — lean mass index, BMCI — bone mineral component index, SMI — skeletal muscle index
There were significant differences between 
COPD1 and COPD2, 3 groups according to the share 
of patients with concomitant AH (c2 = 12.52 and 
c2 = 3.68 respectively). COPD isolated group did 
not differ from COPD plus AH group according 
to age, disease severity and smoking status, 
while BMI was higher in the latter (30 vs. 25.3 
kg/m2; p < 0.05). A similar picture was observed 
concerning the levels of triglycerides (1.59 and 
1.16 μmol/L respectively; p < 0.05) and glucose 
(5.7 and 5.2 μmol/L respectively; p < 0.05). We 
revealed (Table 4) significant difference of all BC 
parameters in COPD patients with concomitant 
AH compared with pure COPD patients. The 
central type of FM deposition (with excess FM 
accumulation in android region) prevailed in 
COPD male patients with concomitant AH.
The leptin and TNF-a level was increased 
during COPD progression by 18%, 75%, 79% and 
by 21%, 52% and 64% respectively in COPD1, 2, 
3 groups compared with the control (p < 0.05 
for COPD2, 3). The level of free testosterone was 
variable, depending on the severity of the disease. 
It was the highest in mild COPD (COPD1) — 7.6 
pg/mL and significantly lower in severe COPD 
(COPD3) — 5.2 pg/mL.
Discussion
BC abnormalities can modulate function-
al limitation in COPD independent of airflow 
obstruction degree. We detected median BMI 
decrease in severe COPD patients against the back-
ground of increased patients share with normal 
BMI during COPD development. Weight loss may 
involve all tissue compartments, although loss of 
skeletal muscle may be particularly important in 
COPD due to wasting of respiratory muscles with 
following loss of their power and endurance [23]. 
BMI did not give the complete information about 
BC changes in our patients because BMI remained 
within the normal range (or slightly increased) in 
most of them. Probably, overweight can reduce the 
cost of breathing in COPD with better mechanical 
efficiency of respiratory muscle. Also advanced 
COPD may accelerate the impact of BC structural 
changes that occur with normal ageing [24]. 
Table 4.  Distribution of body FM in different body regions 
and their relations in COPD patients with/witho-
ut concomitant AH (Me; 25%,75%)
Region COPD isolated
n = 26 
COPD with AH
n = 59 
Arms (%) 18.7
(13.9; 24.6)
24.9*
(20.0; 29.0)
Legs (%) 21.5
(16.6; 25.9)
26.1*
(22.5; 31.0)
Trunk (%) 28.8
(16.9; 35.0)
36.2*
(32.1; 39.2)
Android (%) 31.4
(22.3; 40.6)
41.4*
(36.2; 45.2)
Gynoid (%) 26.8
(21.1; 31.9)
30.2
(26.8; 34.4)
Total level of FM (%) 25.8
(17.3; 30.7)
31.1*
(26.9; 34.5)
Total level of LM (%) 74.2
(69.3; 82.7)
69.3*
(65.5; 72.5)
Android/gynoid 
regions  
1.12
(1.04; 1.27)
1.28*
(1.18; 1.42)
Trunk/total FM 0.56
(0.54; 0.60)
0.61*
(0.58; 0.65)
Legs/total FM  0.30
(0.26; 0.33)
0.26*
(0.24; 0.29)
Arms+legs/trunk 0.71
(0.60; 0.80)
0.59*
(0.51; 0.67)
The designations are the same as in the previous Table 1 
* p < 0,05 between these groups; 
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The level of FMI was increased in COPD1, 2 
(could mask the loss of muscular and bone tis-
sues) and then decreased in COPD3 group. This 
depletion of FMI, LMI, BMCI and SMI in severe 
COPD was largely related to the increased level 
of tissue hypoxia, pulmonary systemic inflamma-
tion (through inflammatory cytokines), intensive 
smoking and catabolic metabolism. Thus, the “fre-
quent exacerbators” (mostly patients with severe 
COPD) had lower levels of these BC parameters. 
This relationship was strengthen by the finding 
of increased circulating levels of CRP and TNF-a 
in severe COPD patients who might have a longer 
exposure to inflammation before entering the 
study. Probably, faster decline in FM, LM, BMCI 
and SMI in severe COPD patients with low BMI 
were significantly related to older age and lower 
FEV1. We can suppose that decrease of BMI, FMI, 
LMI and SMI in severe COPD patients is an adap-
tation to deficient intake of energy and substrates 
as well as it has reduces airflow limitation by 
improving peripheral airway function, because a 
smaller airways are constrained to a greater extent 
by visceral fat than larger airways. Our results 
suggest that disorders of BC distribution occur 
before being underweight. Thus, asymptomatic 
loss of skeletal muscle may occur in up to 25% 
of COPD patients with normal BMI [25].
Depletion of muscle mass (which may be 
roughtly estimated by LMI level) can significantly 
affect peak oxygen consumption and ventilatory 
response in severe COPD patients. LM or SMI 
(as surrogate markers) are still more suitable in 
detecting muscular wasting than BMI due to an 
unapparent and asymptomatic loss of skeletal 
mass [26]. Probably, in COPD the impairment first 
develops in the respiratory muscles strength (that 
is affected more, than peripheral muscle force) 
preceding the obvious changes of pulmonary 
function. 
We cannot detect characteristic changes of 
LMI, SMI and BMCI in mild-to-moderate COPD. 
Probably, DXA method assessed not entirely LM 
or SMI but included smaller and highly meta-
bolically active ectopic FM within and around 
the skeletal muscle and viscera. Therefore, our 
findings in respect to BC distribution in over-
weight COPD men could be to a certain extent 
explained by the excess of ectopic FM. The loss 
of muscle mass was aggravated by infiltration of 
muscles by fat that leads to decreased muscle 
strength and their inadequate functioning. It 
was shown, that intramuscular fat infiltration 
was more pronounced in moderate-to severe 
COPD male patients [27]. There was a positive 
correlation between LMI and SMI (r = 0.87, p < 
0.05) in entire COPD group, showing that they are 
interrelated and reflected the decrease in skeletal 
muscles component. 
The short courses treatment with sCS was 
used only in one moderate COPD patient and 
in three severe COPD patients. Therefore, we 
do not think that our findings can be partially 
explained by the effect of sCS on the repartition 
of FM and LM. 
Segmental BC assessment more often detect-
ed central types of obesity (increase of FM ratio in 
the trunk region to total FM and decreased level 
of legs FM to total FM) than peripheral type in 
our COPD patients. A various distributions of FM 
may have varying mechanical and inflammatory 
properties as well as consequent COPD-related 
effects. Thus, trunk FM (collection of fat compart-
ments with varying metabolic activity) may have 
a greater mechanical impact on diaphragmatic 
movement, chest wall recoil and FVC than FM 
of arms or legs [28]. 
The absence of significant differences be-
tween the control and mild COPD according to the 
distribution of FM in arms, legs and trunk as well 
as the presence of these differences in moderate 
COPD could be due to the fact that skeletal mus-
cle in different body regions may have different 
metabolic and inflammatory effects in advanced 
stage of disease. Probably, the location of smaller 
ectopic fat deposits become more important in 
advanced COPD (due to higher inflammatory 
status) than larger size of fat deposits [29]. 
We detected a direct effect of disturbed BC 
on lung function. There were a significant cor-
relations between LMI, BMCI and FEV1, FVC (r 
= 0.34, 0.39 and r = 0.34, 0.32 respectively) as 
well as dyspnea severity (r = –0.44 and –0.38 
respectively). These correlations indicate that 
decreased muscular and bone tissue components 
of COPD patient’s BC were combined with the 
disorders of lung function and lowered tolerance 
to physical activity. BMCI had a significant cor-
relation with SpO2 and MRC score (r = 0.46 and 
r = –0.36 respectively). These data emphasize a 
negative influence of severe hypoxia on muscu-
lar and bone tissue components of BC in COPD 
patients. Our study revealed increased concentra-
tions of leptin and TNF-a against the background 
of free testosterone level decrease during COPD 
development. Similar changes of leptin and 
TNF-a levels in general COPD group were noted 
(r = 0.32, p < 0.05, n = 82). They may be due 
to the production of these factors by fat tissue. 
Additionally, we detected a significant correlation 
Pneumonologia i Alergologia Polska 2015, vol. 83, no. 6, pages 424–430 
430 www.pneumonologia.viamedica.pl
between free testosterone, leptin level and FMI 
(r = –0.38, 0.33 respectively), indicating that 
low free testosterone level was associated with 
increased body FM in mild-to-moderate COPD 
male patients [17, 30]. The presence of positive 
correlation between FMI and leptin level could 
be explained by the association of intramuscular 
fat with high leptin concentrations and increased 
expression of TNF-a. 
Conclusions
BMI was within the normal range (or was 
even increased) in many of mild-to moderate 
COPD male patients and did not give a comple-
te information about BC changes. The levels of 
FMI, LMI, BMCI and SMI were decreased only 
in severe COPD group, while FMI was increased 
in mild-to-moderate COPD. Severe COPD was 
associated with decreased share of FM in the 
arms, legs, trunk as well as in android and gynoid 
regions. 
Our findings suggest a likely multifactorial 
basis for BC abnormalities in male COPD patients. 
Initially (mild-to-moderate COPD) BMI and BC 
parameters were within the normal range. La-
ter, as COPD progresses, significant changes in 
BC were noted. These findings showed that the 
assessment of BC may be useful clinically for 
evaluation of COPD patients.
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